Lupin Wins US FDA Approval for Modafinil Tablets

Mumbai — Global pharmaceutical major Lupin Limited announced on September 4, 2026, that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) covering Modafinil Tablets USP. The approval permits the company to manufacture and commercialize therapeutic strengths of 100 mg and 200 mg. The rollout aims to expand affordable access to central nervous system agents within the highly regulated American prescription drug market.

Regulatory Clearance and Product Specifications

According to official corporate disclosures and regulatory filings released by Lupin Limited, the approval follows a comprehensive technical review of the company's manufacturing and bioequivalence data.

• Therapeutic Classification: Modafinil is a widely prescribed wakefulness-promoting agent utilized to manage excessive daytime sleepiness associated with conditions like narcolepsy.

• Approved Strengths: The U.S. FDA cleared the commercialization of both 100 mg and 200 mg tablet formulations.

• Manufacturing Standards: Production will adhere strictly to current Good Manufacturing Practices (cGMP) across the firm's certified facilities.

The addition of generic Modafinil strengthens the enterprise's growing neurological portfolio in international markets.

Corporate Background and Market Context

Operating as a leading transnational pharmaceutical enterprise headquartered in Mumbai, Lupin Limited develops and distributes a diverse suite of generic formulations, complex generics, and active pharmaceutical ingredients across global markets. Securing regulatory approvals for essential central nervous system medications reinforces the firm's competitive standing in North America, where demand for cost-effective generic alternatives continues to expand rapidly.

Impact on Patients, Consumers, and Market Competition

For healthcare providers and patients in the United States, the entry of an FDA-approved generic alternative helps lower prescription drug costs while ensuring uncompromised therapeutic efficacy. For commercial channels, broadened supply options mitigate supply chain bottlenecks for critical wakefulness-promoting therapies.

Official Sources Section

Information regarding the regulatory approval and product specifications is sourced from official corporate announcements published by Lupin Limited and regulatory updates issued by the U.S. Food and Drug Administration (FDA).

Quote Section

"According to officials," securing final approval for critical neurological formulations underscores our ongoing commitment to delivering accessible, high-quality generic healthcare solutions to patients globally.

Why It Matters

FDA approvals for generic pharmaceuticals expand patient access to affordable medications and promote healthy market competition. Bringing certified equivalents to the United States market helps reduce overall healthcare expenditure.

Key Facts at a Glance

• Pharmaceutical Company: Lupin Limited.

• Regulator: U.S. Food and Drug Administration (FDA).

• Approved Product: Modafinil Tablets USP (100 mg and 200 mg).

• Therapeutic Category: Central nervous system / wakefulness-promoting agent.

Frequently Asked Questions

What approval did Lupin receive from the U.S. FDA?

Lupin received final approval for its Abbreviated New Drug Application for Modafinil Tablets USP.

What strengths of Modafinil were approved by regulators?

The U.S. FDA approved 100 mg and 200 mg tablet strengths.

What is the primary medical use of Modafinil?

Modafinil is a prescription wakefulness-promoting agent used to treat excessive daytime sleepiness.

Where can official corporate announcements regarding this approval be accessed?

Official press releases are hosted on the Lupin Limited media portal.

Source: Lupin Limited, U.S. Food and Drug Administration (FDA)